09
Oct

After acknowledging a midstage setback for its key respiratory drug benralizumab in COPD last month, AstraZeneca’s big MedImmune division has come back with positive, though somewhat mixed, Phase IIb data underscoring the effectiveness of knocking down eosinophils–white blood cells–in preventing asthma attacks.

…read more

Source: AstraZeneca gets some upbeat asthma data to back would-be IL-5 blockbuster

    

0 No comments